GlassScriptPhysician profile
Ashley N Hilsabeck
NPI 1134495443
$7,871.09
in general payments reported to CMS, 2019-2025
31 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,226 · 2022: $1,752 · 2023: $2,139 · 2024: $1,557 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,892.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,009.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $969.29 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $867.27 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.10 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $618.52 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $564.54 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $464.78 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Renalytix Ai, INC. | $431.41 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Abbott Laboratories | $415.92 | 2021-2025 | Freestyle Libre |
| Pfizer INC. | $381.16 | 2021-2025 | |
| Amgen INC. | $262.36 | 2023-2025 | Repatha, Krystexxa, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $166.24 | 2022 | |
| Daiichi Sankyo INC. | $103.51 | 2021 | |
| Corcept Therapeutics | $93.14 | 2021-2023 | Korlym |
| Exact Sciences Corporation | $93.05 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $89.38 | 2021-2023 | Seglentis, Livalo |
| Grt US Holding, INC. | $87.16 | 2022 | |
| Astellas Pharma US INC | $78.73 | 2023-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $76.97 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $56.96 | 2021 | |
| Averitas Pharma INC. | $50.36 | 2023-2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $40.89 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.91 | 2021 | |
| Biogen, INC. | $27.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.88 | 2023 | Quviviq |
| Dexcom, INC. | $17.85 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.52 | 2023 | Rexulti |
| Medtronic, INC. | $16.31 | 2025 | Inceptiv |
| Avanir Pharmaceuticals, INC. | $16.08 | 2022 | |
| Gilead Sciences, INC. | $13.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Hilsabeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.